Sverre Arne of Sande

Prof. Dr. Sverre Arne of Sande


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1993 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CTC. M. E. Tallaksen
C. M. E. Tallaksen
SSSverre Arne of Sande
Sverre Arne of Sande
TBT. Bøhmer
T. Bøhmer
HBH. Bell
H. Bell
JKJ. Karlsen
J. Karlsen

1 March 2000 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SASayeh F Ahrabi
Sayeh F Ahrabi
GMGrete Madsen
Grete Madsen
KDKnut Dyrstad
Knut Dyrstad
SSSverre Arne of Sande
Sverre Arne of Sande
CGChristina Graffner
Christina Graffner

1 January 1997 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
IHIngrid Henriksen
Ingrid Henriksen
SVSissel R. Våagen
Sissel R. Våagen
SSSverre Arne of Sande
Sverre Arne of Sande
GSGro Smistad
Gro Smistad
JKJan Karlsen
Jan Karlsen

1 February 2009 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
EHEllen Hagesaether
Ellen Hagesaether
MHMarianne Hiorth
Marianne Hiorth
SSSverre Arne of Sande
Sverre Arne of Sande

1 April 2000 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
GSGry Stensrud
Gry Stensrud
SSSverre Arne of Sande
Sverre Arne of Sande
SKSolveig Kristensen
Solveig Kristensen
GSGro Smistad
Gro Smistad

14 October 2013 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
MCMaria Teresa Calejo
Maria Teresa Calejo
SSSverre Arne of Sande
Sverre Arne of Sande
BNBo Nyström
Bo Nyström
This topic is important as it allows for improved specificity in drug delivery, providing possibilities for reduced side effects, and thereby improved pharmacotherapy. As a wealth of different polymers and mechanisms of action has been suggested, a systematic overview of the field is of current importance. This article presents an overview over a selection of thermoresponsive polymers suitable as excipients in systems for gene and drug delivery with particular emphasis on the influence of polymer structure, composition, molecular weight (MW) and architecture on the responsive mechanisms. Due to the immense number of reports on these increasingly popular materials, focus has been restricted to the use of micelle-forming polymers with a lower critical solution temperature, temperature-responsive hydrogels for drug delivery applications and temperature-sensitive polymers as non-viral vectors for polynucleotide delivery. Specific examples covered are poly-(N-isopropylacrylamide) (PNIPAAM), Pluronics and their derivatives. It is concluded that the studies constitute an excellent platform for development of thermoresponsive systems with improved gene and drug delivery properties. A thorough knowledge of factors important for loading efficiency and drug release is necessary to be able to develop optimal nano-carriers for the future. Other issues that are not fully understood is how small the carriers need to be, and which manufacturing procedures should be used.